Ignoring Clustering and Nesting in Cluster Randomized Trials Renders Conclusions Unverifiable [Letter]

Abu Bakkar Siddique, Yasaman Jamshidi-Naeini, Lilian Goltzarri-Arroyo, David B Allison

Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA

Correspondence: David B Allison, Indiana University School of Public Health-Bloomington, 1025 E 7th St, PH 111, Bloomington, IN, 47405, USA, Tel +1 812 855-1250, Email allison@iu.edu; Abu Bakkar Siddique, Indiana University School of Public Health-Bloomington, 1025 E 7th St, SPH 394, Bloomington, IN, 47405, USA, Tel +1 571 274-5328, Email abusiddi@iu.edu

Dear editor

Siraneh et al\(^1\) conducted a clustered randomized controlled trial (cRCT) to test the effectiveness of additional counseling and social support provided by women identified as “positive deviants” to promote exclusive breastfeeding (EBF) within a community. However, their statistical methods did not account for clustering and nesting effects and thus are not valid.

In the study, randomization occurred at the cluster level (ie, kebeles), and mothers were nested within clusters. Three of 6 clusters were in the treatment group and 3 were in the control. Of the 260 mothers, 130 were enrolled in the treatment group and 130 in the control, according to kebele. According to the published statistical methods section, the analyses ignored clustering and nesting effects. Because this is a hierarchical modeling environment and individuals within a cluster are typically positively correlated, an individual-level analysis that does not address clustering effects will generate underestimated standard errors and unduly narrow confidence intervals.\(^2\) That is, the results will overstate statistical significance. Treating the individual-level observations (eg, mothers) as independent units of analysis inflates the type 1 error rate.\(^3\)

One alternative is calculating the mean observation by cluster and analyzing the data at the cluster level. In this case, this approach would reduce the sample size to 6, the same as the number of clusters, resulting in low statistical power. A valid alternative would be to use multi-level hierarchical modeling, which recognizes the hierarchy in the data and accounts for both lower and higher levels as distinct levels simultaneously. Such multi-level modeling estimation will estimate residuals at mother- and kebele-level separately. Statistical packages exist for such modeling.

Moreover, Siraneh et al calculated their sample size based on the randomization of individual participants.\(^1\) In a cRCT, however, sample size and power calculations should account for the number of clusters per condition, average cluster size, and intra-cluster correlation coefficient (ICC).\(^4\)

We requested the deidentified raw data and statistical code from the authors to reproduce their analyses. Even though we pledged to limit our analysis to testing the hypotheses tested in the article, and the Editor-in-Chief deemed our request “appropriate and reasonable”, the authors were unwilling to share their deidentified raw data and statistical code. They said they needed time to analyze the “remaining data” for publication and that the dataset contained identifiers. Thus, we were unable to reanalyze the data using a valid statistical approach accounting for clustering and nesting effects.

Given the analytical methods used, the evidence presented by Siraneh et al\(^1\) neither supports nor refutes whether a positive deviance intervention affects EBF. The analytical methods were incorrect. All authors have an ethical and professional scientific responsibility to correct non-trivial reported errors in published papers.\(^5\) Furthermore, the Committee on Publication Ethics (COPE), in which this journal is a member, states

Edators should consider retracting a publication if they have clear evidence that findings are unreliable, either as a result of major error (e.g., miscalculation or experimental error), or as a result of fabrication (e.g., of data) or falsification.\(^6\)
Funding
ABS, YJ-N, LGA, and DBA are supported by NIH grants R25DK099080, R25HL124208, and the Gordon and Betty Moore Foundation. The opinions expressed are those of the authors and do not necessarily represent those of the NIH or any other organization.

Disclosure
In the last thirty-six months, DBA has received personal payments or promises for same from: Alkermes, Inc.; American Society for Nutrition; Amin Talati Wasserman for KSF Acquisition Corp (Glanbia); Big Sky Health, Inc.; Biofortis Innovation Services (Merieux NutriSciences), Clark Hill PLC; Kaleido Biosciences; Law Offices of Ronald Marron; Medpace/Gelesis; Novo Nordisk Fondren; Reckitt Benckiser Group, PLC; Law Offices of Ronald Marron; Soleno Therapeutics; Sports Research Corp; and WW (formerly Weight Watchers). Donations to a foundation have been made on his behalf by the Northarvest Bean Growers Association. Dr. Allison is an unpaid consultant to the USDA Agricultural Research Service. In the last thirty-six months, Dr. Jamshidi-Naeini has received honoraria from The Alliance for Potato Research and Education. The institution of DBA, ABS, LGA, and YJ-N, Indiana University, and the Indiana University Foundation have received funds or donations to support their research or educational activities from: Alliance for Potato Research and Education; Almond Board; American Egg Board; Arnold Ventures; Eli Lilly and Company; Haas Avocado Board; Gordon and Betty Moore Foundation; Mars, Inc.; National Cattlemen’s Beef Association; USDA; and numerous other for-profit and non-profit organizations to support the work of the School of Public Health and the university more broadly. The authors report no other conflicts of interest in this communication.

References

Dove Medical Press encourages responsible, free and frank academic debate. The contentTxt of the Risk Management and Healthcare Policy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Risk Management and Healthcare Policy editors. While all reasonable steps have been taken to confirm the contentTxt of each letter, Dove Medical Press accepts no liability in respect of the contentTxt of any letter, nor is it responsible for the contentTxt and accuracy of any letter to the editor.

Risk Management and Healthcare Policy
Publish your work in this journal
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy, and preventative measures to promote good health and improve morbidity and mortality in the population. The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/risk-management-and-healthcare-policy-journal

https://doi.org/10.2147/RMHP.S391521

Siddique et al
Dovepress

1896 Dovepress
Risk Management and Healthcare Policy 2022:15

Dovepress

https://doi.org/10.2147/RMHP.S391521